Navigation Links
Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
Date:8/7/2009

SCOTTSDALE, Ariz., Aug. 7 /PRNewswire/ -- Two studies released August 6, 2009 in the New England Journal of Medicine claim to demonstrate that vertebroplasty, a procedure to treat some painful spine fractures, is not effective. According to several authorities in the field, this is incorrect, as both studies actually demonstrate a significant improvement in patients' pain and ability to function normally.

Tory McJunkin, MD, co-founder of Arizona Pain Specialists, has a personal connection because his grandmother recently had the procedure performed with a life-changing, pain-relieving outcome. Dr. McJunkin explained that "Clinical data show that this procedure relieves pain and improves patients' quality of life. I have seen amazing results from vertebroplasty in my practice and for my grandmother."

Allen Burton, MD, Professor of Anesthesiology at MD Anderson in Houston, one of the foremost experts on vertebroplasty, stated, "The conclusion that vertebroplasty does not help back pain is completely wrong. If you look closely at the study design, what they are calling a placebo is actually a facet injection."

"These studies actually show that both treatments are effective," said Paul Lynch, MD, co-founder of Arizona Pain Specialists. "The studies did not use a true control group condition, where patients would receive no treatment. The 'control' patients actually received a different effective treatment and both groups demonstrated highly clinically significant reductions in pain. This demonstrates that vertebroplasty is an effective procedure, although facet injections are also effective."

Pain is often measured on a 0 to 10 scale, with higher numbers indicating greater pain. The studies demonstrate that patients who received the vertebroplasty procedure had reductions in pain of 2.3 and 3.0 points in the two studies, compared to reductions of 1.7 and 2.6 for the facet injection procedure.

Dr. McJunkin said, "Note that patients who received the vertebroplasty procedure had greater reductions in pain, although this was not a statistically significant difference."

To demonstrate statistical differences between groups requires that the study have enough patients for the statistics to have sufficient power to detect the differences. Both studies reported that they were unable to enroll enough patients to have reasonable statistical power. One study noted that they needed 250 patients but only enrolled 131. "The trends in the data demonstrate that if the studies had enough patients, the group receiving vertebroplasty would have had significantly better pain reduction than the other treatment groups," noted Dr. Lynch.

Several large studies have examined and concluded the clinical benefit and efficacy of vertebroplasty for painful vertebral compression fractures. In 2006, Spine Journal released a systematic review of all available data showing 87% relief of pain with vertebroplasty. A 2007 study in the American Journal of Neuroradiology concluded that "Percutaneous Vertebroplasty is a safe and effective method to treat VCF. An immediate improvement in pain is expected for most patients, and disability, mobility, and pain medication use are improved during the short- and long-term periods."

Dr. Lynch agrees with this overall assessment. "Vertebroplasty is only one of several effective treatments, but for some patients it is the best option. These studies, like most studies, have several problems. It would be inappropriate for us to conclude that vertebroplasty is ineffective, as some reports have stated," he concludes.

Arizona Pain Specialists was co-founded by Dr. Paul Lynch and Dr. Tory McJunkin in Scottsdale, AZ. The clinic utilizes a comprehensive model including cutting-edge interventional pain treatments, chiropractic, biofeedback, relaxation therapy and features on-site physio-rehab, an open MRI, procedure center and research department. The clinic's website, www.ArizonaPain.com hosts an online textbook resource and receives more than 35,000 views a month.


'/>"/>
SOURCE Arizona Pain Specialists
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers
2. Arizona Heart Innovative Technologies Licenses New Endovascular Device
3. Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval
4. First Annual Arizona Biotech Day Announced for October 23rd 2008
5. ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies
6. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
7. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
8. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
9. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
10. West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists
11. Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):